Under the terms of the agreement, which will run for 18 months, Proteros will receive research funding fees and success payments for the generation and analyses of protein-ligand-structures of hits and evolved chemical entities from in-house Boehringer Ingelheim programs.
Torsten Neuefeind, CEO of Proteros, said: “By taking advantage of Proteros’ experience and the industrialized processes enabling time- and cost-efficient protein-ligand-structure analyses, Boehringer Ingelheim complements its internal capabilities with our external expertise and access flexible resources.”